ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 135

Assessing Medication Adherence in JIA: Pilot Phase Results from a Single-Center Quality Improvement Initiative

Dori Abel1, Joyce Chang2, Jon Burnham3, Chen Kenyon4 and Sabrina Gmuca5, 1Department of Pediatrics, Division of Rheumatology, Children’s Hospital of Philadelphia; PolicyLab, Children's Hospital of Philadelphia, Philadelphia, PA, 2Boston Children's Hospital, Boston, MA, 3Department of Pediatrics, Division of Rheumatology, Children’s Hospital of Philadelphia; Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 4Department of Pediatrics, University of Pennsylvania Perelman School of Medicine; PolicyLab, Children’s Hospital of Philadelphia, Philadelphia, PA; Leonard Davis Institute of Health Economics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 5Department of Pediatrics, Division of Rheumatology, Children’s Hospital of Philadelphia; Center for Pediatric Clinical Effectiveness, Children’s Hospital of Philadelphia; PolicyLab, Children's Hospital of Philadelphia; Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA

Meeting: 2023 Pediatric Rheumatology Symposium

Keywords: Juvenile idiopathic arthritis, medication, Qualitative Research, quality of care

  • Tweet
  • Email
  • Print
Session Information

Date: Friday, March 31, 2023

Title: Posters: Quality, Health Services, and Education II

Session Type: Poster Session B

Session Time: 5:00PM-6:00PM

Background/Purpose: Suboptimal medication adherence is a widespread problem in JIA. There are several unique features to medication adherence in JIA, including that the medications used are 1) primarily injectable or intravenous with varying administration frequencies, 2) difficult to safely dispose of if unused, and 3) quite expensive. Our pediatric rheumatology practice is currently developing a standardized method for assessing and addressing medication adherence barriers in patients with JIA during clinical care. Through a pilot phase of a quality improvement (QI) initiative, we aimed to test the feasibility of the Barrier Assessment Tool (BAT), created by the Pediatric Rheumatology Care and Outcomes Improvement Network (PR-COIN), within our local clinic setting and to explore perceived barriers and facilitators of adherence among a small sample of patients with JIA and their caregivers to inform future QI and qualitative work, with the long-term goal of improving adherence and minimizing the burden of treatment.

Methods: This single-center, pilot phase, QI study leveraged outpatient visit-level data from a large pediatric rheumatology clinic between May and December 2022 to assess medication adherence in JIA. One provider piloted a brief interview script to prompt discussion about medication adherence during routine clinical visits among a convenience sample of children with JIA and their caregivers. The BAT was administered to caregivers at the same visit.

We retrospectively reviewed responses to adherence interviews and the BAT and manually abstracted clinical information. We reviewed the interview text documented within the visit note to describe responses and summarize commonly reported themes.

Results: A total of 10 patients were included in this study (Table 1). Patients were primarily white females with oligoarticular JIA on subcutaneous medications. Only 30% reported recent missed doses. Most patients reported at least 1 barrier (Figure 1). Patients completed the BAT with ease and expressed the importance of discussing medication adherence.

Table 2 highlights emergent themes from the interviews regarding hypothesized moderators of medication adherence. Barriers included pain and anxiety related to injections, side effects, and forgetfulness. Facilitators included belief that the medication is helpful, injection routines, food rewards, and ease of access.

Conclusion: Our findings suggest that, despite few reports of missed doses, patients with JIA experience significant challenges associated with taking their medications and are interested in discussing them. Patients reported various factors impacting adherence and only some were interested in peer support, suggesting that interventions to address adherence and treatment burden may not be a one-size-fits-all approach.

Given that self-reported adherence is known to overestimate true adherence, our findings should be validated with pharmacy fill data. Our study team aims to conduct a larger study using fill data to measure adherence combined with semi-structured interviews to further explore mechanisms influencing adherence. Future QI work will focus on assessing and addressing adherence barriers on a larger, division-wide scale.

Supporting image 1Categorical values are reported as counts and percentages. Continuous variables are reported as medians and interquartile ranges (IQR).

Supporting image 2Figure 1. Barriers on BAT

Supporting image 3


Disclosures: D. Abel: None; J. Chang: GlaxoSmithKlein(GSK), 5; J. Burnham: None; C. Kenyon: IngenioRx, 12, Member of the Pharmacy and Therapeutics Committee; S. Gmuca: None.

To cite this abstract in AMA style:

Abel D, Chang J, Burnham J, Kenyon C, Gmuca S. Assessing Medication Adherence in JIA: Pilot Phase Results from a Single-Center Quality Improvement Initiative [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 4). https://acrabstracts.org/abstract/assessing-medication-adherence-in-jia-pilot-phase-results-from-a-single-center-quality-improvement-initiative/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2023 Pediatric Rheumatology Symposium

ACR Meeting Abstracts - https://acrabstracts.org/abstract/assessing-medication-adherence-in-jia-pilot-phase-results-from-a-single-center-quality-improvement-initiative/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology